Basit öğe kaydını göster

dc.contributor.authorKaraca, Sibel
dc.contributor.authorKozanoglu, Ilknur
dc.contributor.authorKarakurum Goksel, Basak
dc.contributor.authorKaratas, Mehmet
dc.contributor.authorTan, Meliha
dc.contributor.authorYerdelen, V. Deniz
dc.contributor.authorGiray, Semih
dc.contributor.authorArtier, Zulfikar
dc.date.accessioned2019-12-23T13:38:22Z
dc.date.available2019-12-23T13:38:22Z
dc.date.issued2014
dc.identifier.issn1300-0667
dc.identifier.urihttp://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5370258&blobtype=pdf
dc.identifier.urihttp://hdl.handle.net/11727/4532
dc.description.abstractIntroduction: In this study, we report the results of our experience of therapeutic plasma exchange (TPE) for neuroimmunologic disorders performed at our hospital over a seven-year period. Methods: We retrospectively reviewed the medical records of 91 patients (53 male, 38 female) who had been treated at our center with TPE. Results: 60 patients with Guillain-BarrS syndrome (GBS), 23 with myasthenia gravis (MG), 4 with chronic inflammatory demyelinating polyneuropathy (CIDP) and 1 patient each with polymyositis, septic encephalopathy, acute disseminated encephalomyelitis (ADEM) and Opsoclonus-Myoclonus syndrome (OMS) received TPE. 26.7% of GBS patient's made complete recovery, 61.7% had partial recovery and 11.7% patients died due to respiratory failure. Despite our best efforts and effective TPE treatments, 13.4% of MG patients deceased, however, 78% had full recovery. Three patients with CIDP were discharged with full and 1 patient with partial recovery. The patient with ADEM had partial recovery with TPE at first, but deceased 2 months later due to pneumonia-related respiratory insufficiency. While, patient with polymyositis had slight-partial recovery, we obtained full recovery with TPE in septic encephalopathy and OMS patients. The side effects and complications of treatments with TPE, which included hypotension, hypocalcaemia and anemia, were mild and manageable. Conclusion: The improvement rates were encouraging and we concluded that significant benefit can be achieved with TPE for the treatment of neuroimmunological disorders.en_US
dc.language.isoengen_US
dc.relation.isversionof10.4274/npa.y6879en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTherapeutic Plasma Exchangeen_US
dc.subjectGuillain-Barre syndromeen_US
dc.subjectChronic Inflammatory Demyelinating Polyneuropathyen_US
dc.subjectMyasthenia Gravisen_US
dc.titleTherapeutic Plasma Exchange in Neurologic Diseases: An Experience with 91 Patients in Seven Yearsen_US
dc.typearticleen_US
dc.relation.journalNOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRYen_US
dc.identifier.volume51en_US
dc.identifier.issue1en_US
dc.identifier.startpage63en_US
dc.identifier.endpage68en_US
dc.identifier.wos000334575300012


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster